CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 9 enrolled
Drug / intervention
Domperidonedrug
Likely dose
Domperidone 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01711918
NCT01711918N/ACompleted
CompareCT.gov

Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis

Ron Schey·interventional·Posted Oct 22, 2012·Updated Feb 9, 2018

In Brief

A clinical study evaluating Domperidone for Patients With Gastroparesis Who Have Failed Standard Therapy. Completed, enrolled 9 participants across 1 site.

Detailed Summary

To provide oral domperidone to patients between the ages of 18 and 60 years of age, according to the investigator's judgment, a prokinetic effect is needed for the relief of severe gastroparesis. We have defined severe gastroparesis as 1) positive gastric emptying scintigraphy (more than 10% residue at 4 hours), 2) nausea, 3) early satiety, 4) abdominal pain. We will recruit patients for two years and the patients will be given domperidone for up to two years.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPatients With Gastroparesis Who Have Failed Standard Therapy
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 22, 2012
Enrollment StartJul 1, 2012
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 13.7 years ago

Interventions

Domperidonedrug

oral tablet; dose is 10mg per tablet given up to 3 times daily.